- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06381908
The Effects of Combined Energy and Carbohydrate Restriction on Exercise Capacity (CHO-EX)
The Effects of Combined Energy and Carbohydrate Restriction on Exercise Capacity and Health in Overweight Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Overweight (BMI 25-30), but healthy premenopausal women aged 20-35 years (n=40) will be included in the trial, which is structured as a randomized, parallel group design where participants are randomized to either consume a hypocaloric diet (-1000 kcal) with concurrent carbohydrate restriction (low carbohydrate, L-CHO, n=20) or a similar hypocaloric diet with moderate carbohydrate availability (moderate carbohydrate, M-CHO, n=20). The trial will be single-blinded since it might be transparent to the participants which diet they are consuming, whereas the test personnel collecting and processing test results will be blinded to diet allocation. Diet handling will be managed by specific individuals in the research group who do not partake in executing the physical capacity tests. Additionally, the direction of the trial's primary hypothesis will not be disclosed to the participants to avoid creating preconceived expectations about the effects.
After an initial screening interview and two familiarization visits, participants will complete the intervention period consisting of 10 days with the allocated diet manipulation with preceding and subsequent test days with a series of tests. The tests before and after each test period include measurements of the participants' physical capacity level and energy metabolism in the laboratory as well as blood and muscle sampling. In addition, resting metabolism and body composition will be measured. During each test period, participants' habitual activity level will be monitored with an accelerometer attached to the wrist (Axivity). There will also be monitoring of the activity level with an accelerometer in a 7-day cycle before the start of the trial as a baseline measurement.
Similarly, a glucose monitor will be placed on the upper arm for continuous glucose readings via a Freestyle Libre2 sensor during the trial period.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aarhus C, Denmark, 8000
- Section for Sport Science, Department of Public Health, Aarhus University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 20-35
- BMI: 25-30
Exclusion Criteria:
- Irregular menstruation within the last 6 months (shorter end 24 days or longer end 35 days cycle)
- Injuries / pain in the lower body, which prevents participation in intense cycling
- Medication consumption that may affect primary outcome measures.
- Smoking
- Pregnancy
- Systematic physical activity more than 2 hours per week
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Low-carbohydrate calorie-restriction
Minimum of 3 g carbohydrate/kg body weight/day and a ~1000 kcal calorie restriction
|
Calorie-restriction and low carbohydrate availability
|
|
Experimental: Moderate-carbohydrate calorie-restriction
Maximum of 1 g carbohydrate/kg body weight/day and a ~1000 kcal calorie restriction
|
Calorie-restriction and moderate carbohydrate availability
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to exhaustion
Time Frame: Pre, post (day 11 of the intervention) and follow-up (day 2 after the post measurement)
|
Time to exhaustion at 85% VO2max
|
Pre, post (day 11 of the intervention) and follow-up (day 2 after the post measurement)
|
|
Sprint performance
Time Frame: Pre, post (day 11 of the intervention) and follow-up (day 2 after the post measurement)
|
Peak and mean 15-s sprint performance
|
Pre, post (day 11 of the intervention) and follow-up (day 2 after the post measurement)
|
|
Exercise tolerance
Time Frame: Pre, post (day 11 of the intervention) and follow-up (day 2 after the post measurement)
|
Ratings of perceived exertion (Borg scale) during standardized-intensity exercise from 6 (lowest exertion) to 20 (highest exertion)
|
Pre, post (day 11 of the intervention) and follow-up (day 2 after the post measurement)
|
|
Muscle glycogen levels
Time Frame: Pre and post (day 11 of the intervention)
|
Muscle glycogen levels obtained from biopsy sample
|
Pre and post (day 11 of the intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical activity level
Time Frame: During the intervention (days 1 to 11 of the intervention)
|
Measured with accelerometer during the intervention
|
During the intervention (days 1 to 11 of the intervention)
|
|
Maximal fat oxidation capacity
Time Frame: Pre, post (day 11 of the intervention) and follow-up (day 2 after the post measurement)
|
Maximal fat oxidation measured in the laboratory
|
Pre, post (day 11 of the intervention) and follow-up (day 2 after the post measurement)
|
|
Muscle metabolic enzyme activity
Time Frame: Pre and post (day 11 of the intervention)
|
Activity of key enzymes involved in carbohydrate and fat metabolism
|
Pre and post (day 11 of the intervention)
|
|
Blood lipid profile
Time Frame: Pre and post (day 11 of the intervention)
|
High-density lipoproteins, low-density lipoproteins, very-low-density lipoproteins, cholesterol, free fatty acids and triglycerides
|
Pre and post (day 11 of the intervention)
|
|
Continuous glucose levels
Time Frame: 14 days from the day before the intervention, throughout the intervention (days 1 to 11) and 2 days after the intervention (follow-up)
|
Glucose levels measured continuously across the trial + during exercise tests
|
14 days from the day before the intervention, throughout the intervention (days 1 to 11) and 2 days after the intervention (follow-up)
|
|
Fasting blood glucose and insulin
Time Frame: Pre and post (day 11 of the intervention)
|
Insulin sensitivity (Homa 2 IR)
|
Pre and post (day 11 of the intervention)
|
|
Long-term glycemic control (HbAc1)
Time Frame: Pre and post (day 11 of the intervention)
|
Measured from fasting blood
|
Pre and post (day 11 of the intervention)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1-10-72-19-24
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight and Obesity
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
National University Health System, SingaporeActive, not recruitingObesity | Overweight and/or Obesity | Overweight or Obese Adults | Overweight , ObesitySingapore
-
National Taiwan University HospitalCompleted
-
PfizerNot yet recruitingObesity | Overnutrition | Nutrition Disorders | Overweight | Body Weight | Overweight or Obesity | Overweight and/or Obesity | Nutritional and Metabolic DiseasesUnited States
-
University of Texas Southwestern Medical CenterChildren's Medical Center DallasRecruitingPediatric Obesity | Pediatric Overweight | Overweight , ObesityUnited States
-
Universidade do Extremo Sul Catarinense - Unidade...RecruitingObesity | Overweight and Obesity | Obesity; Endocrine | Overweight, Obesity and Other HyperalimentationBrazil
-
Mexican National Institute of Public HealthUNICEFCompleted
-
Universidade do PortoFundação para a Ciência e a Tecnologia; Administração Regional de Saúde do... and other collaboratorsCompletedOverweight and ObesityPortugal
Clinical Trials on Calorie-restriction with low carbohydrate
-
University of PernambucoUniversidade Federal de PernambucoEnrolling by invitationSarcopenia | Cardiac Disease | Metabolic Disease | Abdominal Obesity | Cardiometabolic SyndromeBrazil
-
University of Texas Southwestern Medical CenterCompletedNon-Alcoholic Fatty Liver DiseaseUnited States
-
Helsinki University Central HospitalActive, not recruiting
-
Allison Sylvetsky (Meni)Children's National Research InstituteCompletedType 1 DiabetesUnited States
-
SINEM BAYRAMCompletedObesity and Metabolic SyndromeTurkey
-
University of CologneFresenius KabiCompletedAcute Renal FailureGermany
-
Rockefeller UniversityCompleted
-
Temple UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompleted
-
University of NottinghamCompletedDiabetes Mellitus Type 2 in ObeseUnited Kingdom